 | | Vol. 14.42 – 10 November, 2022 |
| |
|
|
| LMO2 knockdown in human breast tumors reduced lung metastasis by impairing intravasation, leading to a reduced frequency of circulating tumor cells.
[Science Advances] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors demonstrated that the CoREST complex was a key determinant of endocrine resistance and ER+ breast cancer plasticity.
[Nature Structural & Molecular Biology] |
|
|
|
| Scientists presented a comprehensive analysis of RNA splicing in breast cancer to illustrate the biological function and clinical implications of tumor-specific transcripts arising from these splicing junctions.
[Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Mechanistically, FL-cycE overexpression inhibited the proliferation of human mammary epithelial cells by replication stress and DNA damage accumulation, but low-molecular-weight cyclin-E facilitated replication stress tolerance by upregulating DNA replication and damage repair.
[Oncogene] |
|
|
|
| Both carfilzomib albumin-coated nanocrystals showed similar or higher cytotoxicity than carfilzomib commercial formulation against breast cancer cells.
[Journal of Controlled Release] |
|
|
|
| Direct in vitro co-culture of human TNBC cells with the dorsal root ganglia of adult female mice revealed that TNBC cells adhered to sensory neuron fibers leading to an increase in migration speed.
[npj Breast Cancer] |
|
|
|
| Treatment with a sigma-1 receptor protein (Sig1R) antagonist, 1-(4-iodophenyl)-3-(2-adamantyl)guanidine, activated the unfolded protein response in TNBC (high-Sig1R expressing) and ER + (low-Sig1R expressing) breast cancer cell lines.
[Cancer Gene Therapy] |
|
|
|
| Small interfering RNAs or lentivirus-mediated shRNA was used to silence angiotensin-converting enzyme 2 (ACE2) and HIF-1α expression in cellular models.
[Journal of Translational Medicine] |
|
|
|
| The specific anti-tumor mechanisms of Kruppel like factor 15 (KLF15) were investigated by RNA sequence, RT-qPCR, Western blotting, luciferase assay, ChIP, and bioinformatics analysis.
[Scientific Reports] |
|
|
|
|
| The authors discuss the current standards of care for HER2-positive breast cancer, mechanisms of resistance to HER2-targeted therapy and new therapeutic approaches and agents, including strategies to harness the immune system.
[Nature Reviews Drug Discovery] |
|
|
|
| Scientists summarize the function and main mechanisms of endoplasmic reticulum stress (ERS) in different molecular types of breast cancer, and focus on the development of agents targeting ERS to provide new treatment strategies for breast cancer.
[Cell Communication and Signaling] |
|
|
|
|
| Women with triple negative breast cancer will gain access to pembrolizumab after NHS bosses struck a deal with its manufacturer.
[The Guardian] |
|
|
|
| The number waiting more than the 62-day target time for therapy in the past year has topped 69,000 across England, Northern Ireland and Scotland – twice as many as the same period in 2017-18.
[BBC News] |
|
|
|
|
| March 6 – 8, 2023
Paris, France |
|
|
|
|
|
| | Breast Cancer Research Foundation – New York City, New York, United States (Hybrid) |
|
|
|
| | Imperial College London – London, England, United Kingdom |
|
|
|
| | Baylor College of Medicine – Houston, Texas, United States |
|
|
|
| | AstraZeneca – Mississauga, Ontario, Canada |
|
|
|
| | Ludwig Maximilians University of Munich – Munich, Germany |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
